GERON CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
GERON CORP (GERN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 35.54 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-02
- GERON CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 8.14M shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 12.22M shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 3.35M shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 11.83M shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 35.54M shares, a 20.05% increase from fiscal 2024.
- GERON CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 29.60M shares, a 41.95% increase from fiscal 2023.
- GERON CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 20.86M shares, a 5.61% increase from fiscal 2022.
- GERON CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 19.75M shares, a 106.52% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 8.14M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 20.36M shares derived: sum of 2 quarters · filed 2026-03-02 | 23.71M shares derived: sum of 3 quarters · filed 2026-03-02 | 35.54M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 12.22M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 15.56M shares derived: sum of 2 quarters · filed 2025-11-07 | 27.40M shares 10-Q · filed 2025-11-07 | |
| 2025-06-30 | 3.35M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 15.18M shares 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | 11.83M shares 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | 29.60M shares 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 20.86M shares 10-K · filed 2024-02-28 | |||
| 2022-12-31 | 19.75M shares 10-K · filed 2023-03-16 | |||
| 2021-12-31 | 9.56M shares 10-K · filed 2022-03-10 | |||
| 2020-12-31 | 6.53M shares 10-K · filed 2021-03-11 | |||
| 2019-12-31 | 11.74M shares 10-K · filed 2020-03-12 | |||
| 2018-12-31 | 9.27M shares 10-K · filed 2019-03-07 | |||
| 2017-12-31 | 3.48M shares 10-K · filed 2018-03-16 | |||
| 2016-12-31 | 2.83M shares 10-K · filed 2017-03-01 | |||
| 2015-12-31 | 2.88M shares 10-K · filed 2016-03-10 | |||
| 2014-12-31 | 5.66M shares 10-K · filed 2015-03-11 | |||
| 2013-12-31 | 6.37M shares 10-K · filed 2014-03-17 | |||
| 2012-12-31 | 7.53M shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |